腺苷脱氨酶-1增强生发中心形成及对HIV-1包膜DNA和蛋白疫苗的功能性抗体应答
该研究探讨腺苷脱氨酶-1(ADA-1)作为疫苗佐剂在体内增强疫苗效力的可能性。体外实验显示ADA-1可诱导髓系树突状细胞成熟并促进IL-6分泌;小鼠共免疫HIV-1包膜DNA疫苗与编码ADA-1的质粒可增加TFH细胞频率和HIV结合IgG;联合gp140蛋白免疫时,仅该组小鼠产生可检测的中和抗体应答。研究支持ADA-1作为疫苗佐剂 qualitatively 增强生发中心反应。
要点
- ADA-1在体外诱导髓系树突状细胞成熟并促进IL-6分泌。
- 小鼠共免疫env DNA与pADA可增加TFH细胞频率和血清HIV结合IgG。
- 联合gp140蛋白时仅共免疫pADA组产生可检测的中和抗体应答。
核心结论
- 研究支持ADA-1作为疫苗佐剂用于定性地增强生发中心反应,并代表一种现有治疗药物可快速转化临床使用的新应用。
研究设计与样本
- 体外人类实验及小鼠体内免疫实验,测试ADA-1作为佐剂对HIV-1包膜DNA和蛋白疫苗的增效作用。
主要发现
- 体外实验中,ADA-1诱导髓系树突状细胞成熟,表现为CD40+、CD83+、CD86+和HLA-DR+的mDC频率增加,并促进mDC分泌TFH极化细胞因子IL-6。
- 小鼠共免疫env DNA与pADA后,引流淋巴结中TFH细胞频率显著增加,血清HIV结合IgG增加。
- 小鼠共免疫C亚型env gp160 DNA、pADA并同时免疫匹配的gp140三聚体蛋白后,该组小鼠血清中异源HIV特异性结合IgG显著更多,且仅该组小鼠产生可检测的中和抗体应答。
临床怎么用
- 作者认为这些研究支持ADA-1作为疫苗佐剂用于定性地增强生发中心反应,并代表一种现有治疗药物可快速转化临床使用的新应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adenosine deaminase-1 (ADA-1) plays both enzymatic and non-enzymatic roles in regulating immune cell function. Mutations in the ADA1 gene account for 15% of heritable severe-combined immunodeficiencies. We determined previously that ADA1 expression defines and is instrumental for the germinal center follicular helper T cell (TFH) phenotype using in vitro human assays. Herein, we tested whether ADA-1 can be used as an adjuvant to improve vaccine efficacy in vivo. In vitro, ADA-1 induced myeloid dendritic cell (mDC) maturation as measured by increased frequencies of CD40-, CD83-, CD86-, and HLA-DR-positive mDCs. ADA-1 treatment also promoted the secretion of the TFH-polarizing cytokine IL-6 from mDCs. In the context of an HIV-1 envelope (env) DNA vaccine, co-immunization with plasmid-encoded ADA-1 (pADA) enhanced humoral immunity. Animals co-immunized with env DNA and pADA had significantly increased frequencies of TFH cells in their draining lymph nodes and increased HIV-binding IgG in serum. Next, mice were co-immunized with subtype C env gp160 DNA and pADA along with simultaneous immunization with matched gp140 trimeric protein. Mice that received env gp160 DNA, pADA, and gp140 glycoprotein had significantly more heterologous HIV-specific binding IgG in their serum. Furthermore, only these mice had detectable neutralizing antibody responses. These studies support the use of ADA-1 as a vaccine adjuvant to qualitatively enhance germinal center responses and represent a novel application of an existing therapeutic agent that can be quickly translated for clinical use.
引用
- Gary E, O'Connor M, Chakhtoura M, et al. Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines. Vaccine. 2020. PMID: 32280045. doi:10.1016/j.vaccine.2020.03.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。